{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:23:58Z","timestamp":1790522638931,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["481954\/2013-9"],"award-info":[{"award-number":["481954\/2013-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pr\u00f3-Reitoria de Pesquisa, P\u00f3s-Gradua\u00e7\u00e3o e Inova\u00e7\u00e3o - PROPP","award":["08\/2017"],"award-info":[{"award-number":["08\/2017"]}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais - FAPEMIG","award":["APQ-02357-15"],"award-info":[{"award-number":["APQ-02357-15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Sports Sci Med Rehabil"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The ECA2\/Ang-(1\u20137)\/Mas axis is shown to be involved in effects mediated by physical exercise, as it can induce the release of nitric oxide (ON) and bradykinin (BK), which are potent vasodilators. The vasodilating action the NO\/BK can contribute to increased metabolic efficiency in muscle tissue and central nervous system. The formulation HP\u03b2-CD-Ang-(1\u20137) through its mechanisms of action can be a promising supplement to aid in the maintenance and improvement of performance and may also favor recovery during competitions. The premise of this study was to investigate the effects of acute oral supplementation HP\u03b2-CD-Ang-(1\u20137) on the performance of mountain bike (MTB) practitioners.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fourteen recreational athletes, involved in training programs for at least one year, participated in this crossover design study. Subjects underwent two days of testing with a seven-day interval. HP\u03b2-CD-Ang-(1\u20137) (1.75\u00a0mg) and HP\u03b2CD-Placebo were provided in capsules three hours prior to tests. To determine the safety of the HP\u03b2-CD-Ang-(1\u20137) formulation associated with physical effort, cardiovascular parameters heart rate (HR) and blood pressure (BP) were analyzed. Physical performance was measured using maximal oxygen uptake (VO<jats:sub>2<\/jats:sub>), total exercise time (TET), mechanical work (MW), mechanical efficiency (ME), and rating of perceived exertion (RPE). Respiratory exchange coefficient (REC), lactate and non-esterified fatty acids (NEFAs) were measured. Maximal incremental tests were performed on a progressively loaded leg cycle ergometer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were no significant differences in terms of HR or BP at rest and maximum effort between the HP\u03b2-CD-Ang-(1\u20137) and placebo groups. The VO<jats:sub>2<\/jats:sub>max showed significant differences (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). It was higher in the Ang-(1\u20137)condition (66.15 mlO<jats:sub>2<\/jats:sub>.kg<jats:sup>\u2212\u20091<\/jats:sup>.min<jats:sup>\u2212\u20091<\/jats:sup>) compared to the placebo (60.72 mlO<jats:sub>2<\/jats:sub>.kg<jats:sup>\u2212\u20091<\/jats:sup>.min<jats:sup>\u2212\u20091<\/jats:sup>). This was also observed for TET (Ang-(1\u20137) 39.10\u00a0min vs. placebo 38.14\u00a0min; <jats:italic>p<\/jats:italic>\u2009=\u20090.04), MW (Ang-(1\u20137) 156.7 vs. placebo 148.2; <jats:italic>p<\/jats:italic>\u2009=\u20090.04), and at the lowest RPE (Ang-(1\u20137) vs. placebo; <jats:italic>p<\/jats:italic>\u2009=\u20090.009). No significant differences were observed for REC, NEFAs, or Lactate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results suggest that HP\u03b2-CD-Ang-(1\u20137) improves the physical performance of MTB recreational athletes and could be a promising supplement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>RBR-2\u2009\u00d7\u200956pw8, registered January 15th, 2021. The study was prospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13102-021-00274-4","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T11:02:42Z","timestamp":1620298962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Angiotensin-(1\u20137) oral formulation improves physical performance in mountain bike athletes: a double\u2010blinded crossover study"],"prefix":"10.1186","volume":"13","author":[{"given":"Samara Silva","family":"de Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e1lia T\u00e1ci Pereira","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"de Assis Dias Martins-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1dia L\u00facia","family":"Totou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Barbosa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson Cruz de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Motta-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson Augusto Souza","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenice Kappes","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"2","key":"274_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1152\/physrev.1977.57.2.313","volume":"57","author":"MJ Peach","year":"1977","unstructured":"Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57(2):313\u201370.","journal-title":"Physiol Rev"},{"issue":"5","key":"274_CR2","first-page":"167","volume":"37","author":"L-L Chiu","year":"2005","unstructured":"Chiu L-L, Hsieh L-L, Yen K-T, Hsieh SS. ACE I\/D and ACTN3 R577X polymorphism in elite athletes. Med Sci Sports Exerc. 2005;37(5):167.","journal-title":"Med Sci Sports Exerc"},{"key":"274_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.orcp.2015.09.008","volume":"10","author":"K Kim","year":"2016","unstructured":"Kim K, Ahn N, Park J, Koh J, Jung S, Kim S, Moon S. Association of angiotensin-converting enzyme I\/D and \u03b1-actinin-3 R577X genotypes with metabolic syndrome risk factors in Korean children. Obesity research clinical practice. 2016;10:125\u201332.","journal-title":"Obesity research clinical practice"},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2013.10.022","volume":"51","author":"O Echeverr\u00eda-Rodr\u00edguez","year":"2014","unstructured":"Echeverr\u00eda-Rodr\u00edguez O, Del Valle-Mondrag\u00f3n L, Hong E. Angiotensin 1\u20137 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. Peptides. 2014;51:26\u201330.","journal-title":"Peptides"},{"issue":"5","key":"274_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/CS20140215","volume":"128","author":"F Cisternas","year":"2015","unstructured":"Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y, Cabello-Verrugio C. Angiotensin-(1\u20137) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin Sci. 2015;128(5):307\u201319.","journal-title":"Clin Sci"},{"issue":"6","key":"274_CR6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","volume":"63","author":"RA Santos","year":"2014","unstructured":"Santos RA. Angiotensin-(1\u20137). Hypertension. 2014;63(6):1138\u201347.","journal-title":"Hypertension"},{"issue":"7","key":"274_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/hr.2016.28","volume":"39","author":"D Motta-Santos","year":"2016","unstructured":"Motta-Santos D, Dos Santos RAS, Oliveira M, Qadri F, Poglitsch M, Mosienko V, Becker LK, Campagnole-Santos MJ, Penninger JM, Alenina N. Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise. Hypertens Res. 2016;39(7):506\u201312.","journal-title":"Hypertens Res"},{"issue":"5","key":"274_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1590\/S1807-59322011000500021","volume":"66","author":"RA Fraga-Silva","year":"2011","unstructured":"Fraga-Silva RA, Costa-Fraga FP, Sousa FBD, Alenina N, Bader M, Sinisterra RD, Santos RA. An orally active formulation of angiotensin-(1\u20137) produces an antithrombotic effect. Clinics. 2011;66(5):837\u201341.","journal-title":"Clinics"},{"issue":"10","key":"274_CR9","first-page":"743","volume":"39","author":"LK Becker","year":"2018","unstructured":"Becker LK, Totou N, Moura S, Kangussu L, Mill\u00e1n RDS, Campagnole-Santos MJ, Coelho D, Motta-Santos D, Santos RAS. Eccentric Overload Muscle Damage is Attenuated By a Novel Angiotensin-(1\u20137) Treatment. Chin J Physiol. 2018;39(10):743\u20138.","journal-title":"Chin J Physiol"},{"issue":"5","key":"274_CR10","doi-asserted-by":"publisher","first-page":"e14015","DOI":"10.14814\/phy2.14015","volume":"7","author":"P Dibo","year":"2019","unstructured":"Dibo P, Mara\u00f1\u00f3n RO, Chandrashekar K, Mazzuferi F, Silva GB, Juncos LA, Juncos LI. Angiotensin-(1\u20107) inhibits sodium transport via Mas receptor by increasing nitric oxide production in thick ascending limb. Physiological reports. 2019;7(5):e14015.","journal-title":"Physiological reports"},{"issue":"1","key":"274_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.HYP.0000251865.35728.2f","volume":"49","author":"WO Sampaio","year":"2007","unstructured":"Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL. RM. T: Angiotensin-(1\u20137) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49(1):185\u201392.","journal-title":"Hypertension"},{"issue":"1","key":"274_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1152\/physrev.2001.81.1.209","volume":"81","author":"JS Stamler","year":"2001","unstructured":"Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiological reviews. 2001;81(1):209\u201337.","journal-title":"Physiological reviews"},{"issue":"5","key":"274_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/ATVBAHA.109.200493","volume":"30","author":"SHS Santos","year":"2010","unstructured":"Santos SHS, Braga JF, Mario EG, P\u00f4rto LCJ, Rodrigues-Machado MdGr, Murari A, Botion LM, Alenina N, Bader M, Santos RAS. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1\u20137). Arterioscler Thromb Vasc Biol. 2010;30(5):953\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"274_CR14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1161\/HYPERTENSIONAHA.113.03025","volume":"63","author":"Z Fu","year":"2014","unstructured":"Fu Z, Zhao L, Aylor KW, Carey RM, Barrett EJ, Liu Z. Angiotensin-(1\u20137) recruits muscle microvasculature and enhances insulin\u2019s metabolic action via mas receptor. Hypertension. 2014;63(6):1219\u201327.","journal-title":"Hypertension"},{"key":"274_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2014.05.019","volume":"1573","author":"W Xie","year":"2014","unstructured":"Xie W, Zhu D, Ji L, Tian M, Xu C, Shi J. Angiotensin-(1\u20137) improves cognitive function in rats with chronic cerebral hypoperfusion. Brain research. 2014;1573:44\u201353.","journal-title":"Brain research"},{"issue":"5","key":"274_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/01.HYP.0000143850.73831.9d","volume":"44","author":"MM Gironacci","year":"2004","unstructured":"Gironacci MM, Valera MaS, Yujnovsky I, Pena C. Angiotensin-(1\u20137) inhibitory mechanism of norepinephrine release in hypertensive rats. J Hypertension. 2004;44(5):783\u20137.","journal-title":"J Hypertension"},{"issue":"6","key":"274_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/01.HYP.35.6.1248","volume":"35","author":"MM Gironacci","year":"2000","unstructured":"Gironacci MM, Vatta M, Rodriguez-Fermep\u00edn Mn, Fern\u00e1ndez BE, Pena C. Angiotensin-(1\u20137) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus. J Hypertension. 2000;35(6):1248\u201352.","journal-title":"J Hypertension"},{"issue":"10","key":"274_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2165\/00007256-200636100-00006","volume":"36","author":"R Meeusen","year":"2006","unstructured":"Meeusen R, Watson P, Hasegawa H, Roelands B, Piacentini MF. Central fatigue: the serotonin hypothesis and beyond. Sports Med. 2006;36(10):881\u2013909.","journal-title":"Sports Med"},{"issue":"1","key":"274_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1745-6215-11-32","volume":"11","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1):32.","journal-title":"Trials"},{"issue":"4","key":"274_CR20","first-page":"35","volume":"10","author":"C Machado","year":"2002","unstructured":"Machado C, Caputo F, Lucas R, Denadai B. Physiological and anthropometrical factors associated with uphill off-road cycling performance. Braz J Sci Mov. 2002;10(4):35\u201340.","journal-title":"Braz J Sci Mov"},{"issue":"11","key":"274_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.peptides.2007.08.011","volume":"28","author":"I Lula","year":"2007","unstructured":"Lula I, Denadai \u00c2L, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, Heine T, Duarte HA, Santos RA, Sinisterra RD. Study of angiotensin-(1\u20137) vasoactive peptide and its \u03b2-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides. 2007;28(11):2199\u2013210.","journal-title":"Peptides"},{"issue":"3","key":"274_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","volume":"57","author":"FD Marques","year":"2011","unstructured":"Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, Melo MB, Nadu AP, Souza LE. An oral formulation of angiotensin-(1\u20137) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57(3):477\u201383.","journal-title":"Hypertension"},{"issue":"23","key":"274_CR23","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-09-1957","volume":"15","author":"WJ Petty","year":"2009","unstructured":"Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1\u20137), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009;15(23):7398\u2013404.","journal-title":"Clin Cancer Res"},{"key":"274_CR24","first-page":"3322.3222","volume":"83","author":"WD McArdle","year":"2011","unstructured":"McArdle WD, Katch FI, Katch VL. Fisiologia do exerc\u00edcio: nutri\u00e7\u00e3o, energia e desempenho humano. Traduzido por Giuseppe Taranto 7\u00aa ed Rio Janeiro: Guanabara Koogan. 2011;83:3322.3222.","journal-title":"Traduzido por Giuseppe Taranto 7\u00aa ed Rio Janeiro: Guanabara Koogan"},{"issue":"5","key":"274_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","volume":"14","author":"GA Borg","year":"1982","unstructured":"Borg GA. Psychophysical bases of perceived exertion. Med sci sports exerc. 1982;14(5):377\u201381.","journal-title":"Med sci sports exerc"},{"issue":"5","key":"274_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/bjsm.34.5.367","volume":"34","author":"A Luc\u00eda","year":"2000","unstructured":"Luc\u00eda A, Hoyos J, Chicharro JL. The slow component of VO2 in professional cyclists. Br J Sports Med. 2000;34(5):367\u201374.","journal-title":"Br J Sports Med"},{"key":"274_CR27","doi-asserted-by":"crossref","unstructured":"Ueda S, Masumori-Maemoto S, Wada A, Ishii M, Brosnihan KB, Umemura S. Angiotensin (1\u20137) potentiates bradykinin-induced vasodilatation in man. Journal of hypertension 2001, 19(11).","DOI":"10.1097\/00004872-200111000-00010"},{"issue":"4","key":"274_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/01.HYP.37.4.1136","volume":"37","author":"T Wilsdorf","year":"2001","unstructured":"Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-(1\u20137) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension. 2001;37(4):1136\u201340.","journal-title":"Hypertension"},{"key":"274_CR29","doi-asserted-by":"crossref","unstructured":"Garnacho-Casta\u00f1o MV, Palau-Salv\u00e0 G, Cuenca E, Mu\u00f1oz-Gonz\u00e1lez A, Garc\u00eda-Fern\u00e1ndez P, del C Lozano-Estevan, Veiga-Herreros M, Mat\u00e9-Mu\u00f1oz P, Dom\u00ednguez JL. R: Effects of a single dose of beetroot juice on cycling time trial performance at ventilatory thresholds intensity in male triathletes. J Int Soc Sports Nutr. 2018;15(1):49.","DOI":"10.1186\/s12970-018-0255-6"},{"issue":"6","key":"274_CR30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/ATVBAHA.116.307518","volume":"36","author":"MJ Durand","year":"2016","unstructured":"Durand MJ, Zinkevich NS, Riedel M, Gutterman DD, Nasci VL, Salato VK, Hijjawi JB, Reuben CF, North PE, Beyer AM. Vascular actions of angiotensin 1\u20137 in the human microcirculation: novel role for telomerase. Arterioscler Thromb Vasc Biol. 2016;36(6):1254\u201362.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"274_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/01.HYP.38.1.90","volume":"38","author":"S Sasaki","year":"2001","unstructured":"Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. Effects of angiotensin-(1\u20137) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension. 2001;38(1):90\u20134.","journal-title":"Hypertension"},{"issue":"6","key":"274_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10557-014-6555-4","volume":"28","author":"L Mendon\u00e7a","year":"2014","unstructured":"Mendon\u00e7a L, Mendes-Ferreira P, Bento-Leite A, Cerqueira R, Amorim MJ, Pinho P, Br\u00e1s-Silva C, Leite-Moreira AF, Castro-Chaves P. Angiotensin-(1\u20137) modulates angiotensin II-induced vasoconstriction in human mammary artery. Cardiovascular drugs therapy. 2014;28(6):513\u201322.","journal-title":"Cardiovascular drugs therapy"},{"issue":"1","key":"274_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/01.HYP.37.1.72","volume":"37","author":"H Heitsch","year":"2001","unstructured":"Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1\u20137)\u2013stimulated nitric oxide and superoxide release from endothelial cells. Hypertension. 2001;37(1):72\u20136.","journal-title":"Hypertension"},{"issue":"6","key":"274_CR34","doi-asserted-by":"publisher","first-page":"H1985","DOI":"10.1152\/ajpheart.01145.2002","volume":"284","author":"WO Sampaio","year":"2003","unstructured":"Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1\u20137) in rats. Am J Physiol Heart Circ Physiol. 2003;284(6):H1985\u201394.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"274_CR35","doi-asserted-by":"publisher","first-page":"H2485","DOI":"10.1152\/ajpheart.01245.2006","volume":"292","author":"GA Botelho-Santos","year":"2007","unstructured":"Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, Souza dos Santos RA. Expression of an angiotensin-(1\u20137)-producing fusion protein in rats induced marked changes in regional vascular resistance. American Journal of Physiology-Heart Circulatory Physiology. 2007;292(5):H2485\u201390.","journal-title":"American Journal of Physiology-Heart Circulatory Physiology"},{"issue":"4","key":"274_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1753944715599875","volume":"9","author":"MM Gironacci","year":"2015","unstructured":"Gironacci MM. Angiotensin-(1\u20137): beyond its central effects on blood pressure. Ther Adv Cardiovasc Dis. 2015;9(4):209\u201316.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"1","key":"274_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/hukin-2015-0118","volume":"49","author":"A Zaj\u0105c","year":"2015","unstructured":"Zaj\u0105c A, Chalimoniuk M, Go\u0142a\u015b A, Lngfort J, Maszczyk A. Central and peripheral fatigue during resistance exercise\u2013A critical review. Journal of Human Kinetics. 2015;49(1):159\u201369.","journal-title":"Journal of Human Kinetics"},{"issue":"5","key":"274_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4103\/CJP.CJP_57_19","volume":"62","author":"LK Becker","year":"2019","unstructured":"Becker LK, Totou NL, Oliveira MF, Coelho DB, de Oliveira EC, Motta-Santos D, Silami-Garcia E, Campagnole-Santos MJ, Santos RAS. Lifetime overproduction of circulating angiotensin-(1\u20137) in rats attenuates the increase in skeletal muscle damage biomarkers after exhaustive exercise. Chin J Physiol. 2019;62(5):226\u201330.","journal-title":"Chin J Physiol"}],"container-title":["BMC Sports Science, Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13102-021-00274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13102-021-00274-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13102-021-00274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T03:36:17Z","timestamp":1620358577000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsportsscimedrehabil.biomedcentral.com\/articles\/10.1186\/s13102-021-00274-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1186\/s13102-021-00274-4","relation":{},"ISSN":["2052-1847"],"issn-type":[{"value":"2052-1847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research proposal was approved by the Institutional Review Board of Federal University of Ouro Preto, approved by the Human Research Ethics Committee under protocol no. 25402813.2.1001.5150 and all participants gave written informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, no individual person\u2019s data was presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}